BACKGROUND: Organ donation after cardiac death (DCD) has the potential to alleviate some of the shortage of suitable lungs for transplantation. Only limited data describe outcomes after DCD lung transplantation. This study describes the early and intermediate outcomes after DCD lung transplantation in Canada. METHODS: Data were collected from donors and recipients involved in DCD lung transplantations between June 2006 and December 2008. Described are the lung DCD protocol, donor characteristics, and the occurrence of post-transplant events including primary graft dysfunction (PGD), bronchial complications, acute rejection (AR), bronchiolitis obliterans syndrome (BOS), and survival. RESULTS: Successful multiorgan controlled DCD increased from 4 donors in 2006 to 26 in 2008. Utilization rates of lungs among DCD donors were 0% in 2006, 11% in 2007, and 27% in 2008. The lung transplant team evaluated 13 DCD donors on site, and lungs from 9 donors were ultimately used for 10 recipients. The 30-day mortality was 0%. Severe PGD requiring extracorporeal membrane oxygenation occurred in 1 patient. Median intensive care unit stay was 3.5 days (range, 2-21 days). Hospital stay was 25 days (range, 9-47 days). AR occurred in 2 patients. No early BOS has developed. Nine (90%) patients are alive at a median of 270 days (range, 47-798 days) with good performance status and lung function. One patient died of sepsis 17 months after transplantation. CONCLUSION: DCD has steadily increased in Canada since 2006. The use of controlled DCD lungs for transplantation is associated with very acceptable early and intermediate clinical outcomes.
BACKGROUND: Organ donation after cardiac death (DCD) has the potential to alleviate some of the shortage of suitable lungs for transplantation. Only limited data describe outcomes after DCD lung transplantation. This study describes the early and intermediate outcomes after DCD lung transplantation in Canada. METHODS: Data were collected from donors and recipients involved in DCD lung transplantations between June 2006 and December 2008. Described are the lung DCD protocol, donor characteristics, and the occurrence of post-transplant events including primary graft dysfunction (PGD), bronchial complications, acute rejection (AR), bronchiolitis obliterans syndrome (BOS), and survival. RESULTS: Successful multiorgan controlled DCD increased from 4 donors in 2006 to 26 in 2008. Utilization rates of lungs among DCD donors were 0% in 2006, 11% in 2007, and 27% in 2008. The lung transplant team evaluated 13 DCD donors on site, and lungs from 9 donors were ultimately used for 10 recipients. The 30-day mortality was 0%. Severe PGD requiring extracorporeal membrane oxygenation occurred in 1 patient. Median intensive care unit stay was 3.5 days (range, 2-21 days). Hospital stay was 25 days (range, 9-47 days). AR occurred in 2 patients. No early BOS has developed. Nine (90%) patients are alive at a median of 270 days (range, 47-798 days) with good performance status and lung function. One patient died of sepsis 17 months after transplantation. CONCLUSION: DCD has steadily increased in Canada since 2006. The use of controlled DCD lungs for transplantation is associated with very acceptable early and intermediate clinical outcomes.
Authors: Abbas Emaminia; Damien J Lapar; Yunge Zhao; John F Steidle; David A Harris; Victor E Laubach; Joel Linden; Irving L Kron; Christine L Lau Journal: Ann Thorac Surg Date: 2011-10-31 Impact factor: 4.330
Authors: J J Mooney; H Hedlin; P K Mohabir; R Vazquez; J Nguyen; R Ha; P Chiu; K Patel; M R Zamora; D Weill; M R Nicolls; G S Dhillon Journal: Am J Transplant Date: 2016-02-04 Impact factor: 8.086
Authors: Matthew J Weiss; Laura Hornby; Bram Rochwerg; Michael van Manen; Sonny Dhanani; V Ben Sivarajan; Amber Appleby; Mary Bennett; Daniel Buchman; Catherine Farrell; Aviva Goldberg; Rebecca Greenberg; Ram Singh; Thomas A Nakagawa; William Witteman; Jill Barter; Allon Beck; Kevin Coughlin; Alf Conradi; Cynthia Cupido; Rosanne Dawson; Anne Dipchand; Darren Freed; Karen Hornby; Valerie Langlois; Cheryl Mack; Meagan Mahoney; Deepak Manhas; Christopher Tomlinson; Samara Zavalkoff; Sam D Shemie Journal: Pediatr Crit Care Med Date: 2017-11 Impact factor: 3.624
Authors: Thomas M Egan; Benjamin E Haithcock; Jason Lobo; Gita Mody; Robert B Love; John Jacob Requard; John Espey; Mir Hasnain Ali Journal: J Thorac Dis Date: 2021-11 Impact factor: 3.005
Authors: Ashley Y Choi; Oliver K Jawitz; Vignesh Raman; Michael S Mulvihill; Samantha E Halpern; Yaron D Barac; Jacob A Klapper; Matthew G Hartwig Journal: J Thorac Cardiovasc Surg Date: 2020-05-07 Impact factor: 5.209